<DOC>
	<DOCNO>NCT02036476</DOCNO>
	<brief_summary>This open-label , non-randomized , phase 2 study ass feasibility use cabozantinib recurrent/metastatic Merkel Cell Carcinoma patient progress platinum-based therapy .</brief_summary>
	<brief_title>Cabozantinib Recurrent/Metastatic Merkel Cell Carcinoma</brief_title>
	<detailed_description>Cabozantinib ( XL184 ) inhibitor multiple receptor tyrosine kinase approve U.S. Food Drug Administration ( FDA ) 29 November 2012 treatment patient progressive , metastatic medullary thyroid cancer . It commercially available COMETRIQ™ United States . During Pre Treatment Period , participant consent qualified ( screen ) study . Treatment administer outpatient basis . Each treatment cycle last 28 day , time participant take study drug , cabozantinib , daily . The participant give study drug-dosing diary treatment cycle . The diary also include special instruction take study drug . - Participants follow 8 week removal study death , whichever occur first . Participants remove study unacceptable adverse event follow resolution stabilization adverse event .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<criteria>Must histologically cytologically confirm Merkel Cell Carcinoma metastatic unresectable standard curative measure exist longer effective Must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥10 mm spiral CT scan ( see section 10 evaluation measureable disease ) . Tumors within previously irradiate field designate `` nontarget '' lesion unless progression document Must one prior platinumbased chemotherapeutic regimen management primary disease contain carboplatin , cisplatin another organoplatinum compound . Patients also eligible receive curative intent platinumbased therapy progress within year therapy No prior MET inhibitor allow At least 2 week since prior chemotherapy radiation therapy . At least 3 week since prior biologics investigational agent Recovery effect recent treatment baseline CTCAE ≤ grade 1 toxicity prior therapy except alopecia nonclinically significant AEs Participants must ≥18 year age ECOG performance status ≤1 Participants must normal organ marrow function Women childbearing potential men must agree use adequate contraception prior study entry duration study participation Ability understand willingness sign write informed consent document Collection archival tissue specimens confirmation Merkel Cell Carcinoma Participants chemotherapy radiotherapy within 2 week prior enter study recover adverse event due agent administer 2 week earlier Participants may receive biologics investigational agent within 3 week The subject active brain metastasis epidural disease History allergic reaction attribute compound similar chemical biologic composition cabozantinib Has prothrombin time ( PT ) / International Normalized Ratio ( INR ) partial thromboplastin time ( PTT ) test ≥ 1.3 institutional ULN within 7 day first dose study treatment , unless PT/PTT prolongation know secondary condition associate increase bleed risk ( antiphospholipid antibody syndrome ) Requires concomitant treatment , therapeutic dos , anticoagulant Active bleed pathologic condition carry high risk bleed Have experience clinically significant gastrointestinal bleeding within 6 month first dose study treatment Requires chronic concomitant treatment strong CYP3A4 inducer Is unable unwilling swallow tablet Has correct QT interval calculate Fridericia formula ( QTcF ) &gt; 500 m within 28 day initiation cabozantinib Has evidence tumor invade GI tract evidence endotracheal endobronchial tumor within 28 day first dose cabozantinib Has radiographic evidence cavitating pulmonary lesion ( ) Has uncontrolled , significant intercurrent recent illness Other disorder associate high risk fistula formation include PEG tube placement within 3 month first dose study therapy History major surgery within 3 month minor surgery within 1 month first dose cabozantinib Pregnant woman Individuals history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy HIVpositive individual combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Merkel Cell Carcinoma</keyword>
	<keyword>Skin Cancer</keyword>
</DOC>